Background This post-hoc analysis from three phase 3 treatment trials of rimegepant 75 mg—
an oral small molecule calcitonin gene-related peptide receptor antagonist for acute and …

Background The present study evaluated the long-term safety and tolerability of rimegepant,
an orally administered small molecule calcitonin gene-related peptide receptor antagonist …

Introduction Use of triptans for acute treatment of migraine is associated with insufficient
efficacy and/or tolerability in approximately 30–40% of people. We conducted a systematic …

Background As one of the novel therapeutic drugs that targets Calcitonin gene-related
peptide (CGRP), 75 mg rimegepant has been used for the acute management of migraine …

Objective To determine the potential efficacy of ubrogepant for acute treatment of migraine
based on historical experience with triptans. Background Although triptans have improved …

Importance New therapeutic classes of migraine-specific treatment have been developed,
including 5-hydroxytryptamine 1F receptor agonists (lasmiditan) and calcitonin gene-related …

Background Migraine is the most common neurological condition in developed countries.
The abortive treatment of migraine attacks is important both for quality of life and costs …

Background Although triptans are widely used in the acute management of migraine, there
is uncertainty around the comparative efficacy of triptans among each other and vs non …

Abstract Rimegepant [Nurtec® ODT (USA); Vydura®(EU)] is a calcitonin gene-related
peptide (CGRP) receptor antagonist approved for the acute treatment of migraine with or …

Background: For many years triptans have been the cornerstone of acute migraine
treatment. Nevertheless, treatment with triptans may not always be initiated due to …